Anticuerpos antifosfatidilserina en pacientes con síndrome antifosfolipido primario y en individuos sanos

  • Alexandre Wagner Silva de Souza Rheumatology Division, Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp-EPM), São Paulo, Brasil. Fleury Group, Research and Development, São Paulo
  • Alessandra Dellavance Fleury Group, Research and Development, São Paulo
  • Jéssica Martins Camargo Fleury Group, Research and Development, São Paulo
  • Sonia R. S. Siciliano Fleury Group, Research and Development, São Paulo
  • Emilia Inoue Sato Rheumatology Division, Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp-EPM), São Paulo
  • Luis Eduardo Coelho Andrade Rheumatology Division, Universidade Federal de São Paulo - Escola Paulista de Medicina (Unifesp-EPM), São Paulo, Brasil. Fleury Group, Research and Development, São Paulo
Palabras clave: Síndrome Antifosfolípido, Anticuerpos Antifosfolípidos, Anticuerpos Antifosfatidilserina, Trombosis, Autoanticuerpos

Resumen

Objetivo: Investigar la prevalencia de anticuerpos anti-fosfatidilserina (aFS) de tipo IgM, IgG e IgA en pacientes con síndrome antifosfolípido primario (SAFP) y en controles sanos; analizar la sensibilidad y la especificidad de los anticuerpos aFS para el diagnóstico de aFS y finalmente, evaluar las asociaciones entre los anticuerpos específicos aFS y las manifestaciones clínicas del SAF. Métodos: Estudio transversal de 36 pacientes mujeres con SAFP y 200 donantes de sangre. Se determinaron anticuerpos antifosfatidilserina de tipo IgM, IgG e IgA en pacientes y controles con SAFP utilizando una técnica propia y un kit comercial. A los pacientes com SAFP también se les determinó el anticoagulante lúpico (ACL), los anticuerpos anticardiolipina IgM e IgG (aCL), y los anticuerpos anti-β2 glucoproteína I (anti-β2GPI). Resultados: La prevalencia de los anticuerpos AFS IgM, IgG, IgA en pacientes con SAFP fue la siguiente: 10,8-16,7%, 32,4-35,7%, y 16,1%, respectivamente. Aunque se encontro una sensibilidad relativamente baja para los anticuerpos AFS en el SAFP, la especificidad de los anticuerpos AFS IgM, IgG, IgA para el SAFP fue 94,7-98,9%, 95,3-96,3% y 97,9%, respectivamente. Todos los isotipos de AFS se asociaron significativamente con las manifestaciones obstétricas. Los anticuerpos AFS IgM se asociaron con un riesgo aumentado de trombosis venosa y arterial. Los anticuerpos AFS IgA se asociaron con la trombosis arterial mientras que los anticuerpos AFS IgG se asociaron con un mayor riesgo de eventos trombóticos venosos. Los anticuerpos AFS IgM e IgG se encuentran con frecuencia em asociación con anticuerpos anti-β2GPI. Conclusiones: La prevalencia de anticuerpos AFS es baja en SAFS pero estos anticuerpos son altamente específicos para SAFP y se asocian con manifestaciones SAFP específicos.

Citas

(1) Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498-1509.

(2) L evine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N E ng J Med. 2002;346(10):752-63.

(3) Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun. 2008;30(1-2):74-83.

(4) G alli M, Luciani D, Bertolini G, Bardui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827-32.

(5) O patrny L, David M, Khan SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune diseases: a metaanalysis. J Rheumatol. 2006;33(11):2214-21.

(6) Galli M, Borrelli G, Jacobsen EM, Marfisi RM, Finazzi G, Marchiori R, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood. 2007;110(4):1178-83.

(7) Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev. 2011;10(10):609-16.

(8) Blank M, Tincani A, Shoenfeld Y. Induction of experimental antiphospholipid syndrome in naïve mice with purified IgG antiphosphatidylserine antibodies. J Rheumatol. 1994;21(1):100-4.

(9) Yodfat O, Blank M, Krause I, Shoenfeld Y. The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies lead to the induction of the antiphospholipid syndrome. Clin Immunol Immunopathol. 1996;78(1):14-20.

(10) Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43(9):1982-93.

(11) Hoxha A, Ruffatti A, Tonello M, Bontadi A, Salvan E, Banzato A, et al. Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. Lupus. 2012;21(7):787-9.

(12) Vlagea AD, Gil A, Cuesta MV, Arribas F, Diez J, Lavilla P, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Haemost. 2012. Available from ttp://cat.sagepub.com/content/early/2012/02/27/1076029612437578.long [Accessed on September 17th 2012].

(13) Radway-Bright E, Ravirajan CT, Isenberg DA. The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses. Rheumatology (Oxford). 2000;39(4):427-31.

(14) Musial J, Swadzba J, Motyl A, Iwaniec T. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis. J Rheumatol. 2003;30(4):723-30. 15. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309-11.

(16) Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7(10):1737-40.

(17) G haravi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis. 1987;46(1):1-6.

(18) Viard JP, Amoura Z, Bach JF. Anti-b2-glycoprotein I antibodies and thrombosis. Clin Rev Allergy Immunol. 1995;13(1):67-72.

(19) De Souza AW, Silva NP, de Carvalho JF, D’Almeida V, Noguti MA, Sato EI. Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. Lupus. 2007;16(10):782-7.

(20). Rodrigues CE, Bonfá E, Caleiro MT, Vendramini MB, Bueno C, L opes JB, et al. Coexistance of metabolic syndrome and primary antiphospholipid syndrome is associated with arterial events. Arthritis Care Res (Hoboken). 2012; 64(10):1576-83.

(21) de Souza AW, Keusseyan SP, da Silva NP, Sato EI, Andrade LE. Antinucleosome antibodies and primary antiphospholipid syndrome: na observational study. Rev Bras Reumatol. 2012; 52:357-65.

(22) L opes LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol. 2004; 121(1):142-9.

(23) Kahles T, Humpich M, Steinmetz H, Sitzer M, Lindhoff-Last E. Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischemic stroke. Rheumatology. (Oxford) 2005;44(9):1161-5.

(24) Roggenbuck D, Egerer K, Feist E, Burmester GR, Döner T. Antiphospholipid antibody profiling: associations with the clinical phenotype of antiphospholipid syndrome? Arthritis Rheum. 2012;64(8):2807-8.

(25) Velayuthaprabhu S, Archunan G. Evaluation of anticardiolipin antibodies and antiphosphatidylserine antibodies in women with recurrent abortion. Indian J Med Sci. 2005; 59(8):347-52.

(26) Silver RM, Pierangeli SS, Edwin SS, Umar F, Harris EN, Scott JR, et al. Pathogenic antibodies in women with obstetric features of antiphospholipid syndrome who have negative test results for lupus anticoagulant and anticardiolipin antibodies. Am J Obstet G ynecol. 1997;176(3):628-33.

(27) Devreese KM. Standardization of antiphospholipid antibody assays. Where do we stand? Lupus. 2012;21(7):718-21.

Publicado
2016-03-04
Cómo citar
Souza, A. W. S. de, Dellavance, A., Camargo, J. M., Siciliano, S. R. S., Sato, E. I., & Andrade, L. E. C. (2016). Anticuerpos antifosfatidilserina en pacientes con síndrome antifosfolipido primario y en individuos sanos. Revista Paraguaya De Reumatología, 1(2), 64-72. Recuperado a partir de http://revista.spr.org.py/index.php/spr/article/view/19
Sección
ORIGINALES